↓ Skip to main content

Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19

Overview of attention for article published in Frontiers in immunology, April 2024
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
3 X users

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19
Published in
Frontiers in immunology, April 2024
DOI 10.3389/fimmu.2024.1330178
Pubmed ID
Authors

Garyfallia Poulakou, Pierre-Joseph Royer, Nikolay Evgeniev, Gwénaëlle Evanno, Françoise Shneiker, Anne-Geneviève Marcelin, Bernard Vanhove, Odile Duvaux, Stéphane Marot, Vincent Calvez

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 7 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 14%
Researcher 1 14%
Unknown 5 71%
Readers by discipline Count As %
Unspecified 1 14%
Social Sciences 1 14%
Unknown 5 71%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2024.
All research outputs
#16,675,300
of 26,742,223 outputs
Outputs from Frontiers in immunology
#16,396
of 33,537 outputs
Outputs of similar age
#157,294
of 350,219 outputs
Outputs of similar age from Frontiers in immunology
#275
of 1,123 outputs
Altmetric has tracked 26,742,223 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 33,537 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,219 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 1,123 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.